Navigation Links
BMC awarded NIH grant to study brain abnormalities in former ELGANS patients
Date:9/9/2011

(Boston) Researchers and clinicians from Boston Medical Center (BMC) have been awarded a four year, more than $13 million grant from the National Institutes of Health (NIH) to study neurological and brain abnormalities in former extremely low gestational age newborns (ELGANS). The study will be conducted under the direction of Karl Kuban, MD, chief of pediatric neurology at BMC, who also is the principal investigator of the study. BMC is the lead institution among 14 collaborating organizations across the country participating in this study.

The study, which is scheduled to begin later this month, will build on the ELGAN-1 prospective study of nearly a thousand ELGANs who were evaluated following birth and again at 2 years of age. Of those, 11 percent had cerebral palsy, 40 percent had a developmental quotient below 70, and 11 percent had microcephaly.

As part of the ELGAN-1 study, placenta organisms and histologic characteristics and elevated blood concentrations of proteins during the first postnatal weeks predicted 2-year cognitive and motor impairments and microcephaly. Additionally, 21 percent screened positive for autism spectrum disorders at 2 years.

"Our primary hypothesis is that at 10 years, former ELGANs who had elevated blood concentrations of inflammation-associated biomarkers in the first 2 postnatal weeks are more likely than other former ELGANs to have cognitive, behavioral and neurological disorders and brain structural abnormalities," explained Kuban who also is professor of pediatrics and neurology at Boston University School of Medicine. Ten years was chosen as an age when early adverse neurological problems often manifest with long-term and identifiable educational and quality of life consequences.

The Elgan-2 study will evaluate nearly 1,000 10 year-old ELGAN-1 participants at a dozen institutions in North Carolina, New England and the Midwest. Evaluations will entail direct participant testing and questionnaire/interview activities with the parent/guardian. About 20 percent of the cohort will return on a separate day for an added evaluation for autism (ADOS), and 20 percent will return on a separate day for a brain MRI study.

"In addition to supporting a potential role for many previously identified antecedents of brain damage in ELGANs, our previous study was the first to provide strong evidence that brain damage in extremely preterm infants is associated with microorganisms in placenta parenchyma. We hope to add to those findings thanks to the generosity of this NIH grant," Kuban said.

"We anticipate that this work will help establish a method for identifying infants at high risk as targets for clinical trials of prophylactic and therapeutic interventions. Ultimately, we hope that the result of our work will broaden and redirect the rationale for preventive and therapeutic interventions intended to reduce the risk and severity of neurodevelopmental disorders in ELGANs," added Kuban.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Louisville researcher awarded $12.8 million NIH grant renewal for adult stem cell project
2. Mass. Eye and Ear awarded largest NIH grant in hospital’s history
3. Young investigators awarded for research excellence at Australia meeting
4. Wayne State start-up company NextCAT awarded nearly $500,000 from NSF for Phase II SBIR
5. Southampton researchers awarded $28 million to progress pioneering nutrition and respiratory research
6. BUSM professor awarded $13.3 million to study potential treatments to prevent STDs
7. Lincoln Park Zoo awarded 2 significant grants for science education
8. BUSM awarded $9 million to investigate treatment for sickle cell disease using iPS cells
9. Grants awarded to help bring promising bioscience discoveries to market
10. Johns Hopkins researchers awarded $32 million
11. UTMB-led researchers awarded $7.8 million for Gulf spill study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... BADEN-BADEN, Germany , December 15, 2016 /PRNewswire/ ... services provider, today announced an agreement with NuData Security, ... join forces. The partnership will enable clients to focus on ... with local data protection regulation. ... In order to provide a one-stop ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... ... 23, 2017 , ... AxioMed will be presenting its viscoelastic ... in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the ... experience the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud ... TELEPHONY Product of the Year Award winner for 2017. , For three consecutive ... communications solutions. In 2016, CallTower was awarded with the hosted VoIP Excellence award and ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, a leading ... http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening ... contractors. This is the latest step in G&L’s expansion of its global clinical ...
(Date:1/21/2017)... ... 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New ... receive exclusive marketing and sales rights for all non-OEM Transonic products in Japan. As ... Japan, the new Nipro - Transonic JV is a natural next step to advance ...
Breaking Biology Technology: